OncoMatch/Clinical Trials/NCT05933239

Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

Is NCT05933239 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 68GaNOTA-Anti-MMR-VHH2 for non-small cell lung cancer.

Phase 2RecruitingUniversitair Ziekenhuis BrusselNCT05933239Data as of May 2026

Treatment: 68GaNOTA-Anti-MMR-VHH2 — Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify